Miltefosine 50 mg – Uses, Benefits and Purchasing Information
Miltefosine 50 mg is an oral antiparasitic medicine used for certain parasitic diseases, particularly leishmaniasis caused by susceptible Leishmania parasites. Depending on local regulatory approval and clinical guidance, miltefosine may be prescribed for specific forms of leishmaniasis, including visceral leishmaniasis (kala-azar). Its action interferes with important cellular processes in susceptible parasites, helping treat the infection when the medicine is used according to an appropriate medical regimen.
Miltefosine treatment requires professional diagnosis and supervision because the correct dose and duration depend on the type of infection, body weight, age, kidney and liver function, pregnancy status, and other individual factors. The medicine can cause gastrointestinal adverse effects and may require clinical or laboratory monitoring. It also carries important reproductive safety precautions, particularly because of the risk of harm to an unborn baby.
कैसे उपयोग करें
Follow the prescribed dose: The dose and treatment duration depend on the type of leishmaniasis, body weight, age, geographical region, and the treatment regimen selected by your clinician. Do not determine your dose from online information alone.
Take with food: Swallow the capsule with water during or immediately after a meal, as directed in the product information. Taking it with food may help reduce gastrointestinal side effects.
Complete the prescribed course: Continue treatment for the full duration recommended by your clinician, even if symptoms or skin lesions begin to improve. Do not stop, extend, or change treatment without medical advice.
Manage a missed dose carefully: Follow the instructions provided with your prescription or contact your pharmacist or doctor. Do not take extra capsules to compensate for a missed dose.
Maintain adequate hydration: Nausea, vomiting, and diarrhoea can occur during treatment. Drink adequate fluids as advised by your healthcare professional and seek medical attention if you cannot keep fluids down or develop signs of dehydration.
Attend monitoring appointments: Your doctor may request kidney function tests, liver function tests, and other blood tests during treatment and after completion.
Report serious symptoms: Seek urgent medical attention for severe or persistent vomiting or diarrhoea, reduced urination, yellowing of the skin or eyes, or a blistering or peeling rash.
Follow reproductive precautions: Pregnancy must be ruled out before treatment in women who can become pregnant. Effective contraception is required during treatment and for the specified period afterward.
भंडारण
Store in cool and dry place
Important guidance
Safety advice
Check with your doctor
AlcoholConsult your doctor
Alcohol and Miltefosine 50 mg: Specific evidence regarding a direct interaction between alcohol and miltefosine is limited. However, miltefosine commonly causes nausea, vomiting, and diarrhoea, while alcohol may worsen gastrointestinal discomfort and dehydration. It is advisable to avoid alcohol during treatment and consult your doctor if you have liver disease or other underlying medical conditions.
PregnancyConsult your doctor
Miltefosine 50 mg During Pregnancy: Miltefosine is contraindicated during pregnancy because animal studies have demonstrated potential harm to the developing fetus, including fetal death and birth defects. Women who can become pregnant should have a pregnancy test before starting treatment and use effective contraception during therapy and for the recommended period afterward, generally five months after treatment. Seek immediate medical advice if pregnancy is suspected.
BreastfeedingConsult your doctor
Miltefosine 50 mg While Breastfeeding: The extent to which miltefosine passes into human breast milk is not known. Breastfeeding is not recommended during treatment. Depending on the importance of treatment for the mother, a clinician should advise whether to discontinue the medicine or breastfeeding. Breastfeeding should be avoided for five months after the final dose, according to the WHO-recommended product information.
DrivingConsult your doctor
Driving While Taking Miltefosine 50 mg: Miltefosine may cause nausea, vomiting, diarrhoea, dizziness, or other symptoms that can affect your ability to drive safely. Do not drive, ride a motorcycle, or operate machinery if these symptoms occur. If side effects persist or interfere with everyday activities, contact your healthcare professional for advice.
KidneyConsult your doctor
Miltefosine 50 mg and Kidney Health: Miltefosine treatment may increase serum creatinine and affect kidney function, particularly when vomiting or diarrhoea causes dehydration. Patients with existing kidney disease should inform their doctor before treatment. Kidney function should be monitored during therapy and for four weeks after completion, according to the applicable product information. Safety in severe kidney impairment has not been adequately established.
LiverConsult your doctor
Miltefosine 50 mg and Liver Health: Miltefosine may cause increases in liver enzymes and, in some cases, elevated bilirubin levels. Inform your doctor if you have liver disease, abnormal liver function tests, or a history of liver problems before starting treatment. Your healthcare professional may arrange liver function monitoring during therapy and assess whether miltefosine is appropriate for you.
Clinical review pending
This page uses verified catalogue facts and responsible medicine-information rules. It supports awareness and does not replace a doctor's advice.
